一分钟看懂
这是一项关于肉瘤的II 期研究，登记的药物或干预包括UTD2 + tislelizumab + doxorubicin，当前状态为尚未开始招募。登记地点显示中国成都有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
UTD2 + tislelizumab + doxorubicin · II 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁至70 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- West China Hospital Sichuan University · 成都
公开的入选条件
- 1. Fully understand the purpose, content, process of the trial and possible adverse reactions, voluntarily participate as a subject, and sign the informed consent form;
- 2. Age of 18-70 years old (including 18 and 70 years old) at the time of informed consent (ICF) signing, regardless of gender.
- 3. Histopathologically /cytologically confirmed unresectable locally advanced or metastatic soft tissue sarcoma (classified per the 5th WHO classification, including leiomyosarcoma, liposarcoma, angiosarcoma, epithelioid sarcoma, synovial sarcoma, undifferenti
- 4. No prior systemic anti-tumor therapy for advanced soft tissue sarcoma. For participants with prior neoadjuvant or adjuvant therapy, disease progression must occur \>6 months after the last treatment.
- 5. At least one measurable lesion according to RECIST v1.1 definition.
- 6. ECOG performance status of 0 or 1, with an expected survival of more than 12 weeks.
- 7. Within 1 week before enrollment, the participant's blood routine examination was basically normal, and within 2 weeks before enrollment, the participant did not receive recombinant human granulocyte colony-stimulating factor (rhG-CSF) or blood products/eryt
- Absolute neutrophil count (ANC) ≥1.5×10⁹/L;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07842276；登记信息更新于 2026-09-25。